ArticleCommunications biology2026
SLFN5 restrains type I interferon responses and promotes glioblastoma via its N-terminal Schlafen core domain.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Schlafen 5 (SLFN5) is an important regulator of Type I interferon (IFN-I) signaling and tumorigenesis, yet the structural basis for its biologic activity remains unclear. Here, we dissect functional domains of SLFN5 and uncover a key role for its N-terminal Schlafen core domain in IFN-stimulated gene (ISG) expression and glioblastoma proliferation, independently of the SWAVDL motif and the C-terminal Walker A/B motifs. Partial deletions within the core domain or substitution of two arginine residues (R271E/R326E) near the zinc finger motif disrupt chromatin association and phenocopy SLFN5 loss, including de-repression of ISGs that act as immune checkpoints, such as PD-L1 and PD-L2. In contrast, the C-terminal ATPase/helicase activity is dispensable for transcriptional repression and tumor-promoting functions. Structural comparison of human and mouse SLFN5 revealed a conserved architecture, and experimental evidence demonstrates that murine SLFN5 is a functional ortholog of human SLFN5. These findings establish SLFN5 as a key transcriptional modulator of malignant glioblastoma growth by dampening IFN-I responses and have implications for the development of future immunotherapy approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.